- ►diabetesjournals.org O Schmitz, B Brock, J Rungby - Diabetes, 2004 - Am Diabetes Assoc Amylin is a peptide hormone that is cosecreted with insulin from the pancreatic
ß-cell and is thus deficient in diabetic people. It inhibits glucagon
secretion, delays gastric emptying, and acts as a satiety agent. Amylin ... Cited by 76 - Related articles - BL Direct - All 4 versions
B Nyholm, B Brock, L Ørskov, O Schmitz - eid, 2001 - Informa Pharma Science Amylin is a peptide hormone which is co-secreted with insulin from the pan-
creatic beta-cell. Type 1 diabetic individuals and some Type 2 diabetic individ-
uals are characterised by amylin deficiency. Animal experiments have ... Cited by 13 - Related articles - All 5 versions
- ►diabetesjournals.org PA Hollander, P Levy, MS Fineman, DG Maggs … - Diabetes Care, 2003 - Am Diabetes Assoc RESULTS—Treatment with pramlintide 120 μg BID led to a sustained reduction
from baseline in HbA 1c (−0.68 and −0.62% at weeks 26 and 52, respectively),
which was significantly greater than that seen with placebo (P < 0.05). The ... Cited by 167 - Related articles - BL Direct - All 5 versions
A Kapurniotu - Biopolymers, 2001 - interscience.wiley.com It is also possible that your web browser is not configured or not able to
display style sheets. In this case, although the visual presentation will be
degraded, the site should continue to be functional. We recommend using the ... Cited by 33 - Related articles - BL Direct - All 4 versions
P Hollander, DG Maggs, JA Ruggles, M … - Obesity research, 2004 - ncbi.nlm.nih.gov OBJECTIVE: Several randomized, placebo-controlled, double-blind trials in
insulin-treated patients with type 2 diabetes have shown that adjunctive therapy
with pramlintide reduces hemoglobin (Hb)A1c with concomitant weight loss. ... Cited by 83 - Related articles - BL Direct - All 2 versions
- ►pnas.org LM Yan, M Tatarek-Nossol, A Velkova, A … - Proceedings of the National Academy of Sciences, 2006 - National Acad Sciences Protein aggregation into cytotoxic oligomers and fibrils in vivo is linked to
cell degeneration and the pathogenesis of >25 uncurable diseases, whereas the
high aggregation propensity and insolubility of several bioactive ... Cited by 41 - Related articles - BL Direct - All 11 versions
JB Buse, C Weyer, DG Maggs - Clinical Diabetes, 2002 - Am Diabetes Assoc Long-term intervention studies such as the Diabetes Control and Complications
Trial (DCCT) and the United Kingdom Prospective Diabetes Study (UKPDS) have
clearly demonstrated that intensification of diabetes therapy reduces the ... Cited by 42 - Related articles - BL Direct - All 2 versions
M Fineman, C Weyer, DG Maggs, S Strobel, … - Hormone and metabolic research, 2002 - thieme-connect.com Aims: Amylin is a second beta-cell hormone that is normally co-secreted with
insulin in response to meals; it complements the effects of insulin in
postprandial glucose control, in part by suppressing glucagon secretion. In ... Cited by 92 - Related articles - BL Direct - All 10 versions
DJ Drucker - Nature Clinical Practice Endocrinology and Metabolism, 2005 - glucagon.com INTRODUCTION Before the cDNAs and genes encoding pro glucagon were cloned,
pancreatic glucagon was the prin- cipal proglucagon-derived peptide (PGDP) with
well-characterized biologic actions. However, antisera directed against ... Cited by 59 - Related articles - View as HTML - BL Direct - All 6 versions
SA Amiel, SR Heller, IA Macdonald, SL … - Diabetes Obesity and Metabolism, 2005 - interscience.wiley.com Background: Pramlintide, a human amylin analogue, is a potential new adjunctive
therapy to insulin for patients with type 1 diabetes and insulin-using patients
with type 2 diabetes. Early clinical trials have shown a transient ... Cited by 15 - Related articles - BL Direct - All 4 versions
